Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELVA: QTORIN in Microcystic Lymphatic Malformations
NCT06239480Phase 3Active, not recruiting
- Sponsor
- Palvella Therapeutics
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bezafibrate in microcystic lymphatic malformation (MLM), sponsored by Palvella Therapeutics. Primary endpoint: Investigator Global Assessment for microcystic lymphatic malformations at 24 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
bezafibrate
03
Conditions
microcystic lymphatic malformation (MLM)
Beyond the preview
Go deeper on NCT06239480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239480.